Delivery of interleukin-15 to B16 melanoma by electroporation leads to tumor regression and long-term survival

Technology in Cancer Research and Treatment

Volumn 13, Issue 6, 2014, Pages 551-560

  Marrero, Bernadette ^a   Shirley, Shawna ^b   Heller, Richard ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b OLD DOMINION UNIVERSITY   (United States)

Author keywords

Electroporation; Interleukin 15; Melanoma

Indexed keywords

INTERLEUKIN 15;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESEARCH; CELL PERMEABILIZATION; CONTROLLED STUDY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; LONG TERM SURVIVAL; MELANOMA B16; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; TISSUE INJURY; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; GENE TRANSFER; GENETICS; HUMAN; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; MORTALITY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ELECTROPORATION; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN-15; MELANOMA, EXPERIMENTAL; MICE; PLASMIDS; TUMOR BURDEN;

EID: 84904359653     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.7785/tcrt.2013.600252     Document Type: Article

References (52)

1. Neumann E, Schaefer-Ridder M, Wang Y & Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1, 841-845 (1982). DOI: 0261-4189/82/0107-0841
2. Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J & Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit 11, RA110-121 (2005). DOI: 6257 [pii]
3. Rochlitz CF. Gene therapy of cancer. Swiss Med Wkly 131, 4-9 (2001). DOI: 2001/01/smw-09649
4. Heller LC & Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 17, 890-897 (2006). DOI: 10.1089/hum.2006.17.890
5. Kirkwood JM, Moschos S & Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies cytokines vaccines and combinations. Clin Cancer Res 12, 2331s-2336s (2006). DOI: 10.1158/1078-0432.CCR-05-2538
6. Andre F & Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 11(Suppl. 1), S33-42 (2004). DOI: 10.1038/sj.gt.3302367
7. Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F & Sersa G. The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 74, 2152-2158 (1998). DOI: 10.1016/S0006-3495(98)77924-X
8. Heller LC & Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 10, 312-317 (2010). DOI: ABS-39
9. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL & Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26, 5896-5903 (2008). DOI: 10.1200/JCO.2007.15.6794
10. Heller LC, Cruz YL, Ferraro B, Yang H & Heller R. Plasmid injection and application of electric pulses alter endogenous mRNA and protein expression in B16. F10 mouse melanomas. Cancer Gene Ther 17, 864-871 (2010). DOI: 10.1038/cgt.2010.43
11. Heller LC & Coppola D. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Ther 9, 1321-1325 (2002). DOI: 10.1038/sj.gt.3301802
12. Dayball K, Millar J, Miller M, Wan YH & Bramson J. Electroporation enables plasmid vaccines to elicit CD81 T cell responses in the absence of CD41 T cells. J Immunol 171, 3379-3384 (2003). DOI: 0022-1767/03
13. Tagaya Y, Bamford RN, DeFilippis AP & Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 4, 329-336 (1996). DOI: 10.1016/S1074-7613(00)80246-0
14. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D & Anderson D. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13, 2822-2830 (1994). DOI: 8026467
15. Lodolce JP, Burkett PR, Koka RM, Boone DL & Ma A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev 13, 429-439 (2002). DOI: 10.1016/S1359-6101(02)00029-1
16. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264, 965-968 (1994). DOI: 10.1126/science.8178155
17. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K & Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180, 1395-1403 (1994). DOI: 0022-1007/94/10/1395/01
18. Budagian V, Bulanova E, Paus R & Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 17, 259-280 (2006). DOI: 10.1016/j.cytogfr.2006.05.001
19. Becknell B & Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86, 209-239 (2005). DOI: 10.1016/S0065-2776(04)86006-1
20. Lorenzen I, Dingley AJ, Jacques Y & Grotzinger J. The structure of the interleukin-15 alpha receptor and its implications for ligand binding. J Biol Chem 281, 6642-6647 (2006). DOI: 10.1074/jbc.M513118200
21. Stonier SW & Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 127, 85-92 (2010). DOI: 10.1016/j.imlet.2009.09.009
22. Davies E, Reid S, Medina MF, Lichty B & Ashkar AA. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. J Leukoc Biol 88, 529-536 (2010). DOI:10.1189/jlb.0909648
23. Ohteki T. Critical role for IL-15 in innate immunity. Curr Mol Med 2, 371-380 (2002). DOI: 1012174/1566524023362519
24. Real LM, Jimenez P, Kirkin A, Serrano A, Garcia A, Canton J, Zeuthen J, Garrido F & Ruiz-Cabello F. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 49, 621-628 (2001). DOI: 10.1007/s002620000154
25. Haass NK, Smalley KS, Li L & Herlyn M. Adhesion migration and communication in melanocytes and melanoma. Pigment Cell Res 18, 150-159 (2005). DOI: 10.1111/j.1600-0749.2005.00235.x
26. Li S, Zhang X, Xia X, Zhou L, Breau R, Suen J & Hanna E. Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site. Gene Ther 8, 400-407 (2001). DOI: 10.1038/sj.gt.3301418
27. Heller LC, Ingram SF, Lucas ML, Gilbert RA & Heller R. Effect of electrically mediated intratumor and intramuscular delivery of a plasmid encoding IFN alpha on visible B16 mouse melanomas. Technol Cancer Res Treat 1, 205-209 (2002). DOI: 53007&c54058&p510979&do5detail [pii]
28. Hanari N, Matsubara H, Hoshino I, Akutsu Y, Nishimori T, Murakami K, Sakata H, Miyazawa Y & Ochiai T. Combinatory gene therapy with electrotransfer of midkine promoter-HSV-TK and interleukin-21. Anticancer Res 27, 2305-2310 (2007). DOI: 0250-7005/2007
29. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA & Glass LF. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83, 148-157 (1998). DOI: 10.1002/(SICI)1097-0142(19980701)83:1,148::AID-CNCR20.3.0.CO;2-W
30. Lucas ML, Heller L, Coppola D & Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16. F10 melanoma. Molecular Therapy 5, 668-675 (2002). DOI: 10.1006/mthe.2002.0601
31. Ugen KE, Kutzler MA, Marrero B, Westover J, Coppola D, Weiner DB & Heller R. Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther 13, 969-974 (2006). DOI: 10.1038/sj.cgt.7700973
32. Lucas ML & Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 22, 755-763 (2003). DOI: 10.1089/104454903322624966
33. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD & Weiner DB. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 175, 112-123 (2005). DOI: 175/1/112
34. Jalah R, Rosati M, Kulkarni V, Patel V, Bergamaschi C, Valentin A, Zhang GM, Sidhu MK, Eldridge JH, Weiner DB, Pavlakis GN & Felber BK. Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol 26, 827-840 (2007). DOI: 10.1089/dna.2007.0645
35. Tomayko MM & Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24, 148-154 (1989). DOI: 10.1007/BF00300234
36. Yu WG, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H & Hamaoka T. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol 62, 450-457 (1997). DOI: 9335314
37. Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C & Stoppacciaro A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56, 2531-2534 (1996). DOI: 8653692
38. Wang YS, Li D, Shi HS, Wen YJ, Yang L, Xu N, Chen XC, Chen X, Chen P, Li J, Deng HX, Wang CT, Xie G, Huang S, Mao YQ, Chen LJ, Zhao X & Wei YQ. Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. Clin Cancer Res 15, 6901-6911 (2009). DOI: 10.1158/1078-0432.CCR-09-048439
39. Chu Y, Yang X, Xu W, Wang Y, Guo Q & Xiong S. In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immunother 56, 1539-1549 (2007). DOI: 10.1007/s00262-007-0296-1
40. Bergamaschi C, Jalah R, Kulkarni V, Rosati M, Zhang GM, Alicea C, Zolotukhin AS, Felber BK & Pavlakis GN. Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo. J Immunol 183, 3064-3072 (2009). DOI: 10.4049/jimmunol.0900693
41. Castillo EF & Schluns KS. Regulating the immune system via IL-15 transpresentation. Cytokine 59, 479-490 (2012). DOI: 10.1016/j.cyto.2012.06.017
42. Waldmann TA & Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17, 19-49 (1999). DOI: 10.1146/annurev.immunol.17.1.19
43. Eisenman J, Ahdieh M, Beers C, Brasel K, Kennedy MK, Le T, Bonnert TP, Paxton RJ & Park LS. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 20, 121-129 (2002). DOI: 10.1006/cyto.2002.1989
44. Miklavcic D. Electrical engineering aspects of electroporation drug and gene delivery. Medicon 2001: Proceedings of the International Federation for Medical & Biological Engineering Pts 1 and 2, 15-18 (2001). DOI: 953-184-023-7
45. Lucas ML & Heller R. Immunomodulation by electrically enhanced delivery of plasmid DNA encoding IL-12 to murine skeletal muscle. Mol Ther 3, 47-53 (2001). DOI: 0.1006/mthe.2000.0233
46. Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud A & Heller R. Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12, 3177-3183 (2006). DOI: 10.1158/1078-0432.CCR-05-2727
47. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE & Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 94, 10833-10837 (1997). DOI: 10.1073/pnas.94.20.10833
48. Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM & Weiner GJ. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 92, 3730-3736 (1998). DOI: 006-4971/98/9210-0023
49. Shen W, Waldschmidt M, Zhao X, Ratliff T & Krieg AM. Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. Antisense Nucleic Acid Drug Dev 12, 155-164 (2002). DOI: 10.1089/108729002760220752
50. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation Nat Rev Drug Discov 5, 471-484 (2006). DOI: 10.1038/nrd2059
51. Peng B, Zhao Y, Xu L & Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 25, 2064-2073 (2007). DOI: 10.1016/j.vaccine.2006.11.042
52. Liu J, Kjeken R, Mathiesen I & Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 82, 5643-5649 (2008). DOI: 10.1128/JVI.02564-07